COPENHAGEN, Denmark--(BUSINESS WIRE)--Santaris Pharma announced today promising new findings on the in vitro and in vivo activity of a new class of microRNA-targeted therapeutic candidates developed with its proprietary Locked Nucleic Acid (LNA) technology platform. The new findings were presented this week at 4th Annual Oligonucleotide Therapeutics Society (OTS) Meeting in Boston, Mass.
